LivaNova tops Q2 estimates and lifts 2026 outlook on robust Cardiopulmonary and Neuromodulation momentum
LIVN has more than doubled off its 52-week low of $41.133.
Summary
LivaNova posted Q2 2026 revenue of $390.6M (+10.8% reported), beating estimates, and raised full-year revenue and EPS guidance. A new supply agreement with Thermo Fisher and a favorable tax ruling add to the positive momentum.
Updates
· SEC 10-Q — The 10-Q confirms Q2 net income of $108.6M, diluted EPS of $1.93, and revenue of $390.6M.
Key Events · Earnings and Guidance · LIVN
-
Q2 Revenue and EPS Beat
Revenue of $390.6M grew 10.8% reported (9.8% constant-currency), driven by Cardiopulmonary (+11.2%) and Neuromodulation (+10.1%). Adjusted diluted EPS of $1.26 exceeded the prior year's $1.05.
-
Full-Year Guidance Raised
2026 constant-currency revenue growth guidance raised to 8-9% (from 7-8%); adjusted diluted EPS guidance raised to $4.30-$4.40 (from $4.20-$4.30). Adjusted free cash flow guidance lowered to $140M-$160M (from $160M-$180M) to fund capacity expansion and IT investments.
-
Thermo Fisher Supply Agreement
Entered into a long-term agreement with Thermo Fisher Scientific to secure a critical oxygenator component, expected to increase manufacturing output and meet unmet demand over time.
-
Italian Tax Benefit
Received a favorable ruling from the Italian tax authority resulting in a discrete tax benefit of €81.8M ($95.4M) related to the deductibility of the SNIA environmental liability.
Analysis · LIVN · Industrial Applications And Services
A strong second quarter saw revenue reach $390.6M, a 10.8% reported increase that beat expectations, while adjusted EPS of $1.26 easily surpassed the prior year's $1.05. Confidence in sustained momentum across both Cardiopulmonary and Neuromodulation prompted management to raise full-year constant-currency revenue growth guidance to 8–9% and adjusted EPS to $4.30–$4.40. A new long-term supply agreement with Thermo Fisher Scientific is set to ease oxygenator component constraints, supporting future output. A favorable Italian tax ruling contributed a one-time $95.4M benefit, though adjusted free cash flow guidance was trimmed to $140M–$160M to fund strategic investments. With the stock trading near its 52-week high, these results reinforce the growth narrative.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIVN was trading at $87.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $41.13 to $85.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.